Efficacy and safety of the BNT162b2 mRNA COVID-19 vaccine in participants with a history of cancer: subgroup analysis of a global phase 3 randomized clinical trial

INTRODUCTION: Individuals with an underlying malignancy have high risk of poor COVID-19 outcomes. In clinical trials, COVID-19 vaccines were safe and efficacious against infection, hospitalization, and death, but most trials excluded participants with cancer. We report results from participants with...

Descripción completa

Detalles Bibliográficos
Autores principales: Thomas, Stephen J., Perez, John L., Lockhart, Stephen P., Hariharan, Subramanian, Kitchin, Nicholas, Bailey, Ruth, Liau, Katherine, Lagkadinou, Eleni, Türeci, Özlem, Şahin, Ugur, Xu, Xia, Koury, Kenneth, Dychter, Samuel S., Lu, Claire, Gentile, Teresa C., Gruber, William C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8702495/
https://www.ncbi.nlm.nih.gov/pubmed/35131133
http://dx.doi.org/10.1016/j.vaccine.2021.12.046

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8702495/
https://www.ncbi.nlm.nih.gov/pubmed/35131133
http://dx.doi.org/10.1016/j.vaccine.2021.12.046

Ejemplares similares